Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) major shareholder Bain Capital Life Sciences Inv sold 254,110 shares of the firm's stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $30.51, for a total transaction of $7,752,896.10. Following the sale, the insider owned 10,194,048 shares of the company's stock, valued at $311,020,404.48. This represents a 2.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Bain Capital Life Sciences Inv also recently made the following trade(s):
- On Thursday, April 30th, Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock. The stock was sold at an average price of $29.23, for a total transaction of $27,732,167.11.
- On Wednesday, April 29th, Bain Capital Life Sciences Inv sold 797,133 shares of Heartflow stock. The stock was sold at an average price of $29.37, for a total transaction of $23,411,796.21.
- On Wednesday, February 4th, Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00.
Heartflow Price Performance
Shares of NASDAQ HTFL opened at $29.76 on Friday. The company has a 50 day simple moving average of $26.11 and a 200-day simple moving average of $29.28. The company has a market capitalization of $2.55 billion and a P/E ratio of -14.95. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $41.22.
Hedge Funds Weigh In On Heartflow
A number of hedge funds have recently made changes to their positions in HTFL. Wellington Management Group LLP purchased a new position in shares of Heartflow during the 3rd quarter worth approximately $164,263,000. Baillie Gifford & Co. purchased a new position in Heartflow in the 3rd quarter valued at approximately $101,182,000. Schusterman Interests LLC purchased a new position in Heartflow in the 3rd quarter valued at approximately $65,274,000. Capricorn Investment Group LLC purchased a new position in Heartflow in the 4th quarter valued at approximately $48,178,000. Finally, Vanguard Group Inc. purchased a new position in Heartflow in the 3rd quarter valued at approximately $48,871,000.
Analysts Set New Price Targets
HTFL has been the subject of a number of research analyst reports. Canaccord Genuity Group increased their price objective on shares of Heartflow from $40.00 to $43.00 and gave the stock a "buy" rating in a research report on Thursday, March 19th. JPMorgan Chase & Co. lowered their price objective on shares of Heartflow from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, March 19th. Finally, Wells Fargo & Company lowered their price objective on shares of Heartflow from $38.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, March 19th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Heartflow currently has a consensus rating of "Moderate Buy" and an average target price of $37.67.
Check Out Our Latest Stock Analysis on HTFL
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
